ArticleReproductive toxicology (Elmsford, N.Y.)2022
Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M
Article in Reproductive toxicology (Elmsford, N.Y.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Efficacy and Safety of Antivirals in Lactating Women with Herpesviridae Infections: A Systematic Review.Viruses · 2025Pooled it
- Preclinical Toxicological evaluation of the HIV entry inhibitor peptide 2P23 as a candidate rectovaginal microbicide.Scientific reports · 2026Article
- Birth Outcomes Following Anti-viral Therapy for Treatment of COVID-19 During Pregnancy.Maternal and child health journal · 2025Article
- COVID-19 Antiviral Medication Use Among Pregnant and Recently Pregnant US Outpatients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Effect of Paxlovid on Skeletal System Morphogenesis in Animal Model Rat (Morphological Study).Medical journal of the Islamic Republic of Iran · 2025Article
- Prolonged course of Paxlovid administration in a centenarian with COVID-19: A case report.World journal of radiology · 2024Article
- The anti-COVID-19 drug Paxlovid crosses biological barriers of the placenta and brain in rats.Npj viruses · 2024Article
- Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.European journal of medicinal chemistry · 2023Review
- Adverse outcomes in SARS-CoV-2-infected pregnant mice are gestational age-dependent and resolve with antiviral treatment.The Journal of clinical investigation · 2023Article
- Antiviral Treatment of Coronavirus Disease-2019 Pneumonia.Clinics in chest medicine · 2023Review
- Nirmatrelvir-Ritonavir (Paxlovid) for Mild Coronavirus Disease 2019 (COVID-19) in Pregnancy and Lactation.Obstetrics and gynecology · 2023Article
- Management of Coronavirus Disease-2019 Infection in Pregnancy.Emergency medicine clinics of North America · 2023Review
- Interaction of Laurusides 1 and 2 with the 3C-like Protease (MInternational journal of molecular sciences · 2023Article
- Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection.Journal of pharmaceutical analysis · 2023Review
- COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Xenobiotics).Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2023Review
- Paxlovid (Nirmatrelvir and Ritonavir) Use in Pregnant and Lactating Woman: Current Evidence and Practice Guidelines-A Scoping Review.Vaccines · 2023Article
- European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild/moderate disease.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Article
- Analysis of Clinical Outcomes of Pregnant Patients Treated With Nirmatrelvir and Ritonavir for Acute SARS-CoV-2 Infection.JAMA network open · 2022Article
- Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.Clinical microbiology reviews · 2022Review
- New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.Antimicrobial agents and chemotherapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nirmatrelvir (PF-07321332; NMV) the antiviral component of PAXLOVID™ is a potent and selective inhibitor of the SARS-CoV-2 main protease (M
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.